OPT 821/822

There are two different trials. One is focused on Breast Cancer (relevant for this forum), the other is for Ovarian Cancer (less relevant for the forum).

For those that are curious, the Breast Cancer clinical trial exploits the concept of "Active immunotherapy". This approach uses a patient's own immune system by activating and training it to recognize and kill tumor cells. OBI-822 is a first-in-class active immunotherapy against breast cancer. For those patients who experience severe side effects from chemo or other therapies, OBI-822 represents a viable alternative that may offer a dramatic improvement in their quality of life.
OBI-822 is a conjugate of Globo H and KLH (no idea what this means). It is exclusively licensed to OBI from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City.

"Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects"
Official Title: A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer

Estimated Enrollment: 342
Study Start Date: December 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)

Sponsor: OBI Pharma, Inc (Headquarters are in Taiwan)

Locations: The ongoing OBI-822 Clinical Trial is presently conducted in over 40 sites in multiple countries including: the US, Taiwan, Korea, India, and Hong Kong.

If the OP is requesting info on the "Ovarian Cancer" trial, that info can be found here:
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer